Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ridgeback Biotherapeutics
Miami, Florida, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Ridgeback Biotherapeutics is a privately held infectious-disease-focused biotechnology company founded in 2016, best known for co-developing the oral antiviral molnupiravir (LAGEVRIO) for COVID-19 with Merck and for ansuvimab-zykl (EBANGA), an Ebola monoclonal antibody therapy; both products have achieved regulatory approvals in major markets, establishing Ridgeback as a late-stage and commercial-stage developer in emerging and orphan infectious diseases.[1][2][5]
- Therapeutic areas
- Rare DiseasesInfectious Diseases
- Modalities
- Monoclonal antibodyBiologicSmall moleculeVaccine
- Industry
- Biotech
02
Partnerships
Merck & Co. (clinical development and commercialization partnership for molnupiravir/LAGEVRIO)[2][3]National Institute of Allergy and Infectious Diseases (NIAID) – licensing of Ebola monoclonal antibody mAb114/ansuvimab (EBANGA)[5]Emory University – exclusive license for molnupiravir[2]
Beyond the preview
Go deeper on Ridgeback Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ridgeback Biotherapeutics.